Clinical Trial Update: A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and biological activity of FG-3019 in combination with gemcitabine and erlotinib in locally advanced or metastatic pancreati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• FG-3019 (pamrevlumab) (pamrevlumab)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Kyntra Bio | Conditions: Locally Advanced or Metastatic Pancreatic Cancer | Phase 1 | Status: COMPLETED